EU panels backs approval of Ariad's Iclusig for leukemia

03/25/2013 | American City Business Journals

Ariad Pharmaceuticals' Iclusig, or ponatinib, was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use as a treatment for chronic, accelerated or blast-phase chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD